SNIPR Biome

Overview
News
Human Gene Editing?
Product stageSegments
Seed
?
R&D therapies: CRISPR/Cas9 technology, Gene editing: SaaS platforms
?

Denmark-based SNIPR Biome develops novel CRISPR and microbiome-based therapeutics for various therapeutic areas, including infectious diseases, oncology, and immuno-oncology. The company uses its patented technology to directly target the unfavorable bacteria associated with the disease without affecting the favorable parts of the bacteria.

As of March 2024, the company had six programs in its therapeutic pipeline, all of which were in the preclinical and discovery stages, except its lead and first development candidate SNIPR001—for the prevention of infections in cancer patients with hematological malignancies—which commenced its first-in-human Phase I clinical trial in April 2022.

The company’s intellectual property consists of 22 granted US patents and more than 130 pending patent applications. SNIPR was reportedly the first to receive US and European patents for CRISPR/microbiome technology. As of 2022, it had covered over 100 bacterial species across more than 100 therapeutic indications. 

Key customers and partnerships

The company partnered with The University of Texas MD Anderson Cancer Center in September 2021 to develop novel CRISPR-based microbiome therapeutics to reduce immune-related adverse events (irAE) in cancer patients. 

Funding and financials

In March 2019, SNIPR Biome raised USD 50 million in a Series A funding round led by LSP and Lundbeckfonden Emerge to accelerate the development of its CRISPR platform and clinical pipeline. It also received USD 3.9 million from CARB-X in May 2021 to develop a novel therapeutic to prevent cancer patients from being infected with E.Coli, a bacteria usually present in intestines. SNIPR was also eligible for additional milestone payments.

HQ location:
Lersø Parkallé 44 Copenhagen DNK
Founded year:
2017
Employees:
11-50
IPO status:
Private
Total funding:
USD 62.6 mn
Last Funding:
-
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.